Compare Adaptive Biotechnologies Corp (ADPT) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Church & Dwight Co., Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while Church & Dwight Co., Inc. trades at $96.08 (market cap $23.45B). The key difference: Church & Dwight Co., Inc. is far larger — about 7× Adaptive Biotechnologies Corp's market cap, and Church & Dwight Co., Inc. pays a 1.41% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CHD | |
|---|---|---|
Market Cap | $3.33B | $23.45B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $105.26 |
52-Week Low | $10.24 | $81.60 |
Enterprise Value | $3.19B | $25.15B |
Dividend Yield | — | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Church & Dwight (CHD) trades at $98.95, up 0.35% with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q1 2026 adjusted EPS of $0.95 beating the $0.93 estimate (Zacks Investment Research, 2026-05-01). Recent acquisition of Miss Mouth's brand for $325 million strengthens its fabric care portfolio. Valuation metrics show a P/E of 32.43 and ROE of 16.78%, indicating premium pricing but strong profitability.
Outlook remains positive with 53% analyst buy ratings and a $100.50 consensus target, though net cash flow turned negative in 2025. Risks include cost pressures impacting margins, as seen in Q1 profit slippage (WSJ, 2026-05-01), and high debt levels. The stock offers growth potential through organic sales expansion and strategic acquisitions, but investors should monitor margin sustainability and competitive dynamics in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
